Research a compound stack end to end — a structured protocol scaffold, how VialTalk researchers actually combine these compounds, receptor conflicts, and live COA-verified prices. Add 1–5 compounds.
Research signals
Redundancy, true conflicts, and dangerous additive effects
Conflicts found
1 flagged interaction found
Receptor activity map
| Receptor | Dual Incret… | Amylin Anal… | KPV | PE-22-28 |
|---|---|---|---|---|
| GLP-1R (Glucagon-like peptide-1 receptor) | ||||
| GIPR (Glucose-dependent insulinotropic polypeptide receptor) | ||||
| AMY1-3 (Amylin receptor complexes / calcitonin receptor) | ||||
| Gastric emptying / GI motility axis | ||||
| TREK-1 (Two-pore-domain potassium channel) | ||||
| AKT/mTOR/PPARγ / ROS-inflammatory signaling |
A structured, research-grounded protocol for this stack
Sign in to build a structured research protocol scaffold for PE-22-28 + Amylin Analog + Dual Incretin Agonist + KPV — phases, per-compound parameters, endpoints and washout, grounded in documented research.
What VialTalk researchers actually run
No researchers have logged this exact combination yet — yours could be the first.
Researchers are also adding
Best price for each compound today
Same “From” price shown on each compound's page (after discounts). Panels = COA assays tested. Tap “Compare all vendors” for the full breakdown.
For research and informational use only. VialTalk does not provide medical advice or dosing guidance. Community data reflects self-reported public research journals.